Henrylactones A-E and anti-HBV constituents from Illicium henryi.
Five new sesquiterpene lactones, henrylactones A-E ( 1- 5), together with ten known compounds: cycloparvifloralone ( 6), tashironin ( 7), tashironin A ( 8), neoanisatin ( 9), anisatin ( 10), anislactone B ( 11), 7- O-acetylanislactone B ( 12), merrillianolide ( 13), cyclomerrillianolide ( 14) and pseudomajucin ( 15), were isolated from the stems and roots of ILLICIUM HENRYI. Their structures were elucidated based on extensive spectroscopic data analyses. Among them, henrylactone A ( 1) is a novel sesquiterpene with a dilactone moiety and its structure was confirmed by X-ray diffraction. Sesquiterpene lactones 1- 15 were tested for their anti-hepatitis B virus (HBV) activities. The most active compound, tashironin ( 7), exhibited an IC (50) value of 0.48 mM (SI = 6.3) inhibiting on HBV surface antigen (HBsAg) secretion and an IC (50) value of 0.15 mM (SI = 20.1) inhibiting on HBV e antigen (HBeAg) secretion using HBV transfected Hep G2.2.15 cell line.
Liu
Ji-Feng
JF
State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, Yunnan, PR China.
Jiang
Zhi-Yong
ZY
Zhang
Quan
Q
Shi
Yao
Y
Ma
Yun-Bao
YB
Xie
Ming-Jin
MJ
Zhang
Xue-Mei
XM
Chen
Ji-Jun
JJ
D000998:Antiviral Agents / Q000302:isolation & purification* / Q000494:pharmacology / Q000627:therapeutic use; D056945:Hep G2 Cells; D006509:Hepatitis B / Q000188:drug therapy*; D006514:Hepatitis B Surface Antigens / Q000378:metabolism; D006513:Hepatitis B e Antigens / Q000378:metabolism; D006515:Hepatitis B virus / Q000187:drug effects*; D006801:Humans; D029523:Illicium / Q000737:chemistry*; D007783:Lactones / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use; D015394:Molecular Structure; D010936:Plant Extracts / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use; D018517:Plant Roots; D018547:Plant Stems; D012717:Sesquiterpenes / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use
D000998:Antiviral Agents; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D007783:Lactones; D010936:Plant Extracts; D012717:Sesquiterpenes